ACH on NYSE

Owens & Minor

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons4

Healthcare logistics company

Accendra Health is a global healthcare company. It employs over 20,000 people in 70 countries.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

1882Founded1

Compare with Patterson Companies, Henry Schein or Teladoc, or pick any stock.

  • TickerACH on NYSE1
  • Industryhealth care1
  • HeadquartersMechanicsville1
  • Websiteowens-minor.com
  • Incorporated inVA5
  • Business address4435 Waterfront Drive, Suite 300, Glen Allen, Va5
  • Filer categoryLarge accelerated filer5

Accendra Health is a global healthcare company. It employs over 20,000 people in 70 countries. A Fortune 500 company, it was founded in 1882 in Richmond, Virginia, where it remains headquartered. The company has distribution, production, customer service and sales facilities located across the Asia Pacific region, Europe, Latin America, and North America. President and CEO Ed Pesicka joined Owens & Minor in March 2019.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

1.0%Operating margin7
-39.8%Net margin7
3.1%Revenue growth, 20257

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Diabetes Product brought in 28% of the revenue Owens & Minor broke down this way in fiscal 2025.

  1. Diabetes Product$783.4M728%up 1% from 2024
  2. Sleep Therapy Product$740.1M727%up 5% from 2024
  3. Home Respiratory Therapy Product$433.1M716%down 1% from 2024
  4. Product and Service, Other$288.2M710%up 7% from 2024
  5. Ostomy$212.8M78%up 9% from 2024
  6. Wound Care$188.5M77%down 2% from 2024
  7. Urology$116.0M74%up 8% from 2024
Products and services by year
Products and services202320242025
Diabetes Product$723.3M$777.5M$783.4M
Sleep Therapy Product$669.8M$703.0M$740.1M
Home Respiratory Therapy Product$457.7M$436.0M$433.1M
Product and Service, Other$255.0M$268.3M$288.2M
Ostomy$177.9M$195.9M$212.8M
Wound Care$170.9M$192.4M$188.5M
Urology$98.0M$107.1M$116.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue53¢$1.5B
  • Selling, general and admin39¢$1.1B
  • Other costs4¢$113.8M
  • Interest4¢$107.2M
  • Income tax0¢$729.0K

Out of $2.8B in revenue.7 The company lost money this year.

Financial statements

Revenue8910117$2.8B in 2025−70% since 2019
0$2.5B$5.0B$7.5B$10.0B2019: $9.2B$9.2B20192020: $8.5B$8.5B2020−8%2021: $9.8B$9.8B2021+15%2022: $10.0B$10.0B2022+2%2023: $2.6B$2.6B2023−74%2024: $2.7B$2.7B2024+5%2025: $2.8B$2.8B2025+3%
Gross profit891011$2.2B in 2024+97% since 2019
0$1.0B$2.0B$3.0B2019: $1.1B$1.1B20192020: $1.3B$1.3B2020+13%2021: $1.5B$1.5B2021+18%2022: $1.8B$1.8B2022+21%2023: $2.1B$2.1B2023+16%2024: $2.2B$2.2B2024+4%
Operating income8910117$27.5M in 2025−62% since 2019
-$400.0M-$200.0M0$200.0M$400.0M2019: $73.2M$73.2M20192020: $204.1M$204.1M2020+179%2021: $368.5M$368.5M2021+81%2022: $142.9M$142.9M2022−61%2023: $133.2M$133.2M2023−7%2024: -$217.7M-$217.7M20242025: $27.5M$27.5M2025
Net income8910117-$1.1B in 2025+1665% since 2019
-$1.5B-$1.0B-$500.0M0$500.0M2019: -$62.4M-$62.4M20192020: $29.9M$29.9M20202021: $221.6M$221.6M2021+642%2022: $22.4M$22.4M2022−90%2023: -$41.3M-$41.3M20232024: -$362.7M-$362.7M2024+778%2025: -$1.1B-$1.1B2025+203%

Every line of the income statement in the latest annual report, as filed.7

Period ending2025-12-312024-12-312023-12-31
Net revenue$2.8B$2.7B$2.6B
Cost of net revenue$1.5B$1.4B$1.3B
Selling, general and administrative expenses$1.1B$1.1B$1.0B
Goodwill impairment charge$0$307.1M
Transaction breakage fee$80.0M
Acquisition-related charges and intangible amortization$95.8M$61.8M$74.8M
Exit and realignment charges, net$18.4M$46.8M$7.3M
Total operating costs and expenses$2.7B$2.9B$2.4B
Operating income (loss)$27.5M-$217.7M$133.2M
Interest expense, net$107.2M$107.6M$116.8M
Transaction financing fees, net$18.3M$0$0
Other expense, net$3.9M$4.6M$1.2M
(Loss) income from continuing operations before income taxes-$102.0M-$329.9M$15.3M
Income tax provision$729.0K$20.9M$6.4M
(Loss) income from continuing operations, net of tax-$102.7M-$350.7M$8.9M
Loss from discontinued operations, net of tax$998.0M$12.0M$50.2M
Net loss-$1.1B-$362.7M-$41.3M
(Loss) income from continuing operations, net of tax (in dollars per share)-$1-$5$0
Loss from discontinued operations, net of tax (in dollars per share)-$13-$0-$1
Net loss per common share Basic (in dollars per share)-$14.31-$4.73-$0.54
(Loss) income from continuing operations, net of tax (in dollars per share)-$1-$5$0
Loss from discontinued operations, net of tax (in dollars per share)-$13-$0-$1
Net loss per common share Diluted (in dollars per share)-$14.31-$4.73-$0.53

Compare Owens & Minor with another company

The story

Owens & Minor originally opened as a pharmacy company in downtown Richmond, Virginia in 1882, inside a historic building which still stands today. The company continued this business for over half a century until, in 1954, Gil Minor, Jr. bought out Bodeker Drug Company, a smaller operation in the same industry, changing the company name to Owens, Minor & Bodeker.

In 1966, the company acquired Virginia A&J Hospital Supply, adding medical and surgical distribution to its portfolio. By 1970, OMB had opened Cardinal Drug Centers, merchandising its products to independent drug companies, stocking shops with over 25,000 items within two years. Around this time, disposable items were distributed to hospitals for various medical procedures. G. Gilmer Minor III, a direct relation to the founder, became CEO in 1984. By 1988, Owens & Minor began trading on the New York Stock Exchange under the ticker OMI. It was around this time that revenues earned the company a Fortune 500 ranking.

By 1999, the company had refocused toward medical supply chain management. Throughout the 2000s, Owens & Minor acquired various medical distributors across the United States, notably the hospital distributor McKesson Medical-Surgical Inc., a business unit of McKesson, for $152.1 million, on September 30, 2006. In 2012, it entered the European market, opening offices in Spain, France, Germany, Poland, and the Czech Republic after the acquisition of Movianto Group. In 2014, the corporation acquired ArcRoyal, a privately held medical kit company based in Dublin, Ireland.

In 2018, it acquired Halyard Health’s Surgical & Infection Prevention business for $710 million, the largest acquisition in the company’s history. Halyard is a manufacturer of sterilization wrap, facial protection products, exam gloves, protective apparel, surgical drapes and surgical gowns.

In May 2022, Owens & Minor stated that 45 percent of the items it offers are in some way supply-constrained due to the 2021–2022 global supply chain crisis. The following month, the company broke ground in Morgantown, West Virginia for a 350,000 square-foot medical supplies and logistics center, to be completed in late 2023, which will include dedicated acute care medical distribution facilities and clinical supply capabilities.

In July 2024, the company announced it had agreed to acquire medical equipment firm Rotech Healthcare for $1.36 billion. However, the companies terminated the deal in June 2025, citing regulatory hurtles. As a result, the Owens & Minor paid Rotech an $80 million termination payment.

From Wikipedia’s article on Accendra Health, shared under CC BY-SA 4.0.6

Leadership

Who has led Owens & Minor, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (73)

Products and brands

On December 31 2025, Owens & Minor, Inc. announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc.

From Wikipedia’s article on Accendra Health, shared under CC BY-SA 4.0.6

Former names

  • OWENS & MINOR INC/VA/Aug 10, 1994 to Dec 31, 20255
  • O&M HOLDING INCJun 17, 1994 to Jun 17, 19945
  • OWENS & MINOR INCApr 22, 1994 to Mar 9, 19945

Timeline

  1. Oct 6, 2026New chief executive Kenneth Gardner-Smith becomes CEO16
  2. Mar 2, 2023New chief executive Perry A. Bernocchi becomes CEO17
  3. Nov 14, 2022New chief executive Andrew G. Long becomes CEO18
  4. Mar 7, 2019New chief executive Edward A. Pesicka becomes CEO19
  5. Jul 1, 2015New chief executive Paul Cody Phipps becomes CEO20
  6. Sep 3, 2014New chief executive James L. Bierman becomes CEO21
  7. Feb 5, 2007New chief executive Craig R. Smith becomes CEO22
  8. Aug 13, 2003New chief executive G. Gilmer Minor Iii. becomes CEO23
  9. 1882Founded Founded1

Recent filings

  1. Oct 9, 20268-K
  2. Oct 7, 2026SCHEDULE 13G
  3. Oct 6, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  4. Sep 28, 20268-K/A
  5. Sep 24, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  6. Sep 17, 20268-K
  7. Sep 11, 2026144
  8. Aug 17, 20268-K
  9. Aug 10, 20268-K
  10. Aug 10, 20268-K
  11. Aug 10, 202610-Q
  12. Aug 10, 20268-K
  13. Aug 10, 20268-A12B
  14. Jul 24, 2026EFFECT
  15. Jul 15, 2026S-3

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109